Endometrial cancer is the most widely recognized gynecologic danger in the United States of America. Even though the majority of endometrial cancer cases present are at the beginning phases, the patients who are diagnosed with advanced stages of the disease, or develop a recurring or metastatic version of cancer happen to have a less fortunate outcome. A deficiency of mismatch repair (MMR) can be seen in a subgroup of endometrial cancers. It was perceived that tumors lacking in MMR are especially vulnerable to programmed death-ligand 1 (PD-L1) or programmed cell death protein (PD-1) inhibitors. Pembrolizumab was given fast-tracked permission to be used against such tumors by the U.S Food and Drug Administration in a landmark judgment in 2017. This was the first-ever tumor-agnostic permission of a drug. However, there is not much information about the sensitivity to programmed cell death protein (PD-1) among patients who are known to have mutations in double-strand break DNA repair pathways including homologous recombination like those in BRCA1 or BRCA2. Here the researchers provide an account of a patient diagnosed with a germline BRCA1 as well as a forceful, physical endometrial cancer lacking in MMR who encountered a quick, complete respite to pembrolizumab.
Link:theoncologist.onlinelibrary.wiley.com/doi/10.1634/theoncologist.2017-0526
